These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 31795298)

  • 41. Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer.
    Yang L; Li G; Zhao L; Pan F; Qiang J; Han S
    Tumour Biol; 2014 Oct; 35(10):9759-67. PubMed ID: 24972969
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 43. EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation.
    Li Y; Li Y; Zhang H; Shi R; Zhang Z; Liu H; Chen J
    BMC Pulm Med; 2021 Jun; 21(1):190. PubMed ID: 34090412
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma.
    An R; Wang Y; Voeller D; Gower A; Kim IK; Zhang YW; Giaccone G
    Oncotarget; 2016 May; 7(20):29199-210. PubMed ID: 27078848
    [TBL] [Abstract][Full Text] [Related]  

  • 45. F-circEA1 regulates cell proliferation and apoptosis through ALK downstream signaling pathway in non-small cell lung cancer.
    Huo Y; Lv T; Ye M; Zhu S; Liu J; Liu H; Song Y
    Hum Cell; 2022 Jan; 35(1):260-270. PubMed ID: 34633654
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The biology and treatment of EML4-ALK non-small cell lung cancer.
    Sasaki T; Rodig SJ; Chirieac LR; Jänne PA
    Eur J Cancer; 2010 Jul; 46(10):1773-80. PubMed ID: 20418096
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
    Bokhari AA; Lai WY; Le AT; Gabre JL; Chuang TP; Fransson S; Bergman B; Djos A; Chen N; Martinsson T; Van den Eynden J; Doebele RC; Palmer RH; Hallberg B; Umapathy G
    Lung Cancer; 2022 Sep; 171():103-114. PubMed ID: 35933914
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy.
    Kanaji N; Bandoh S; Ishii T; Tadokoro A; Watanabe N; Takahama T; Haba R; Imataki O; Dobashi H; Matsunaga T
    Lung Cancer; 2012 Aug; 77(2):293-8. PubMed ID: 22494566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.
    Katayama R
    Cancer Sci; 2018 Mar; 109(3):572-580. PubMed ID: 29336091
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs.
    Cheon SY; Kwon S
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982897
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing.
    Moskalev EA; Frohnauer J; Merkelbach-Bruse S; Schildhaus HU; Dimmler A; Schubert T; Boltze C; König H; Fuchs F; Sirbu H; Rieker RJ; Agaimy A; Hartmann A; Haller F
    Lung Cancer; 2014 Jun; 84(3):215-21. PubMed ID: 24674157
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.
    Normant E; Paez G; West KA; Lim AR; Slocum KL; Tunkey C; McDougall J; Wylie AA; Robison K; Caliri K; Palombella VJ; Fritz CC
    Oncogene; 2011 Jun; 30(22):2581-6. PubMed ID: 21258415
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
    Chen Y; Ma G; Su C; Wu P; Wang H; Song X; Yu Q; Zeng A; Zhou S
    Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Non-small cell lung cancer patients with EML4-ALK fusion gene are insensitive to cytotoxic chemotherapy.
    Morodomi Y; Takenoyama M; Inamasu E; Toyozawa R; Kojo M; Toyokawa G; Shiraishi Y; Takenaka T; Hirai F; Yamaguchi M; Taguchi K; Seto T; Sugio K; Ichinose Y
    Anticancer Res; 2014 Jul; 34(7):3825-30. PubMed ID: 24982409
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.
    Nanjo S; Nakagawa T; Takeuchi S; Kita K; Fukuda K; Nakada M; Uehara H; Nishihara H; Hara E; Uramoto H; Tanaka F; Yano S
    Cancer Sci; 2015 Mar; 106(3):244-52. PubMed ID: 25581823
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
    Kim SJ; Kim S; Kim DW; Kim M; Keam B; Kim TM; Lee Y; Koh J; Jeon YK; Heo DS
    Cancer Res Treat; 2019 Jul; 51(3):1231-1240. PubMed ID: 30653748
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
    Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
    J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correlation of anaplastic lymphoma kinase overexpression and the EML4-ALK fusion gene in non-small cell lung cancer by immunohistochemical study.
    Chen TD; Chang IC; Liu HP; Wu YC; Wang CL; Chen YT; Chen YR; Huang SF
    Chang Gung Med J; 2012; 35(4):309-17. PubMed ID: 22913857
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SIRT1 silencing promotes EMT and Crizotinib resistance by regulating autophagy through AMPK/mTOR/S6K signaling pathway in EML4-ALK L1196M and EML4-ALK G1202R mutant non-small cell lung cancer cells.
    Yang Q; Sun K; Gao T; Gao Y; Yang Y; Li Z; Zuo D
    Mol Carcinog; 2024 Nov; 63(11):2133-2144. PubMed ID: 39078281
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ZYY-B-2, a novel ALK inhibitor, overcomes resistance to ceritinib by inhibiting P-gp function and induces apoptosis through mitochondrial pathway in ceritinib-resistant H2228 cells.
    Gao Y; Liu T; Liu J; Yang Y; Sun K; Li Z; Zhai X; Zuo D
    Chem Biol Interact; 2023 Jul; 379():110516. PubMed ID: 37116853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.